4.4600
-0.1800
(-3.88%)
At close: January 31 at 4:00:01 PM EST
4.4600
0.00
(0.00%)
After hours: January 31 at 5:25:03 PM EST
Insider Purchases Last 6 Months
Shares | Transactions | |
---|---|---|
Purchases | 503,425 | 3 |
Sales | 78,904 | 6 |
Net Shares Purchased (Sold) | 424,521 | 9 |
Total Insider Shares Held | 129.92k | -- |
% Net Shares Purchased (Sold) | -144.30% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
Shares | |
---|---|
Net Shares Purchased (Sold) | -- |
% Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
Insider | Transaction | Type | Value | Date |
---|---|---|---|---|
VIGNOLA MARK J. Chief Financial Officer | Sale at price 5.72 - 5.80 per share. | Direct | 99,024 | Jan 6, 2025 |
QUIGLEY JILL M. Director | Sale at price 5.72 - 5.79 per share. | Direct | 86,460 | Jan 6, 2025 |
KURIAKOSE EMIL T. Officer | Sale at price 5.71 per share. | Direct | 25,607 | Jan 2, 2025 |
LU HONGBO B Director | Purchase at price 10.50 per share. | Indirect | 4,999,995 | Sep 12, 2024 |
VIGNOLA MARK J. Chief Financial Officer | Conversion of Exercise of derivative security at price 5.36 per share. | Direct | 53,600 | Sep 10, 2024 |
VIGNOLA MARK J. Chief Financial Officer | Sale at price 11.00 per share. | Direct | 110,000 | Sep 10, 2024 |
QUIGLEY JILL M. Director | Conversion of Exercise of derivative security at price 1.82 per share. | Direct | 31,368 | Sep 9, 2024 |
QUIGLEY JILL M. Director | Sale at price 10.00 per share. | Direct | 172,350 | Sep 9, 2024 |
QUIGLEY JILL M. Director | Sale at price 7.50 - 7.68 per share. | Direct | 113,580 | Aug 2, 2024 |
QUIGLEY JILL M. Director | Conversion of Exercise of derivative security at price 1.82 per share. | Direct | 26,872 | Jul 16, 2024 |
GORDON CARL L Director and Beneficial Owner of more than 10% of a Class of Security | Sale at price 10.00 per share. | Indirect | 561,640 | Jul 16, 2024 |
ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Sale at price 10.00 per share. | Indirect | 561,640 | Jul 16, 2024 |
QUIGLEY JILL M. Director | Sale at price 10.00 per share. | Direct | 147,660 | Jul 16, 2024 |
YOON SEOKHO BRYAN Chief Operating Officer | Purchase at price 6.01 per share. | Direct | 28,794 | May 31, 2024 |
VIVO OPPORTUNITY LLC Beneficial Owner of more than 10% of a Class of Security | Sale at price 6.20 - 6.99 per share. | Indirect | 2,796,859 | Apr 3, 2024 |
YOON SEOKHO BRYAN Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
VIGNOLA MARK J. Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
QUIGLEY JILL M. Officer and Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
QUIRK ERIN M.D. Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Jan 23, 2024 |
YOON SEOKHO BRYAN Chief Operating Officer | Purchase at price 3.78 per share. | Direct | 2,809 | Nov 30, 2023 |
QUIGLEY JILL M. Officer and Director | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Nov 15, 2023 |
SUNDARAM SENTHIL VEL Chief Executive Officer | Purchase at price 10.61 per share. | Direct | 22,398 | May 31, 2023 |
YOON SEOKHO BRYAN Chief Operating Officer | Purchase at price 10.61 per share. | Direct | 106,068 | May 31, 2023 |
Related Tickers
ALT Altimmune, Inc.
6.64
-5.14%
GPCR Structure Therapeutics Inc.
29.97
-1.15%
ETNB 89bio, Inc.
9.60
-0.41%
MDGL Madrigal Pharmaceuticals, Inc.
334.80
-1.03%
MLTX MoonLake Immunotherapeutics
45.99
-2.40%
CRDF Cardiff Oncology, Inc.
4.0300
+1.51%
VKTX Viking Therapeutics, Inc.
32.75
-2.79%
IOVA Iovance Biotherapeutics, Inc.
5.85
-5.80%
ARVN Arvinas, Inc.
17.61
-1.57%
FDMT 4D Molecular Therapeutics, Inc.
5.60
0.00%